Posted by Michael Wonder on 21 Feb 2017
Roche receives EU approval of Alecensa (alectinib) for people with previously treated ALK-positive non-small-cell lung cancer
21 February 2017 - Alecensa provides an efficacious, systemic treatment option for people with ALK-positive non-small-cell lung cancer, which is also active in patients with brain metastases, who have been previously treated with crizotinib.
Roche announced today that the European Commission has granted a conditional marketing authorisation for Alecensa (alectinib) as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.
Most people with ALK-positive NSCLC develop resistance to the current standard of care within one year of treatment, and approximately 60% will develop metastases in the central nervous system.
